SCHEMBL7090145

SCHEMBL7090145

Cc1cc(Cl)cc(C(O)(C(=O)c2ccccc2)c2ccccc2)c1-c1ccc(F)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK4 O00444 2/20 0.37
DAPK3 O43293 2/20 0.37
RPS6KA5 O75582 2/20 0.37
MAP4K4 O95819 2/20 0.37
PIM1 P11309 2/20 0.37
PHKG2 P15735 2/20 0.37
CDK2 P24941 2/20 0.37
AXL P30530 2/20 0.37
AKT1 P31749 2/20 0.37
AKT2 P31751 2/20 0.37
PRKCI P41743 2/20 0.37
MAPKAPK2 P49137 2/20 0.37
CLK2 P49760 2/20 0.37
GSK3A P49840 2/20 0.37
GSK3B P49841 2/20 0.37
IRAK1 P51617 2/20 0.37
RPS6KA3 P51812 2/20 0.37
NEK2 P51955 2/20 0.37
PLK1 P53350 2/20 0.37
CSNK1G2 P78368 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089416 0.81 CYP2C9 (0.37) PLK4DAPK3RPS6KA5MAP4K4PIM1
SCHEMBL7085175 0.76 DDR1 (0.34) PLK4DAPK3RPS6KA5MAP4K4PIM1
SCHEMBL7084404 0.76 NR3C2 (0.41) SMN1; SMN2HTTALDH1A1MEN1MAPT
SCHEMBL7091315 0.76 CYP2C9 (0.35) CYP2C9SMN1; SMN2L3MBTL1ALDH1A1MEN1
SCHEMBL7089413 0.74 DDR1 (0.35) PLK4DAPK3RPS6KA5MAP4K4PIM1
SCHEMBL7089474 0.69 PPARG (0.39) CYP2C9KCNN4ALDH1A1MAPTCES1
SCHEMBL7085442 0.68 SLC6A4 (0.39) SMN1; SMN2MEN1MAPTHTR1EKMT2A
SCHEMBL7084394 0.68 PTGS2 (0.48)
SCHEMBL8799598 0.68 KCNN4 (0.46) CYP2C9KCNN4ALDH1A1MEN1MAPT
SCHEMBL8800479 0.68 KCNN4 (0.51) PLK4DAPK3RPS6KA5MAP4K4PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 PLK4 2101/4885DAPK3 1336/4885RPS6KA5 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.